Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab, durva) + bevacizumab (BEV) in bev-naive patients with recurrent glioblastoma (GBM) Meeting Abstract
| Authors: | Reardon, D.; Kaley, T.; Dietrich, J.; Clarke, J.; Dunn, G.; Lim, M.; Cloughesy, T.; Gan, H.; Park, A.; Schwarzenberger, P.; Ricciardi, T.; Macri, M.; Ryan, A.; Venhaus, R. |
| Abstract Title: | Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab, durva) + bevacizumab (BEV) in bev-naive patients with recurrent glioblastoma (GBM) |
| Meeting Title: | 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology |
| Journal Title: | Neuro-Oncology |
| Volume: | 20 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2018 Nov 15-18 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-11-01 |
| Start Page: | vi10 |
| Language: | English |
| ACCESSION: | WOS:000460646300035 |
| PROVIDER: | wos |
| PMCID: | PMC6216117 |
| DOI: | 10.1093/neuonc/noy148 |
| Notes: | Meeting Abstract: ATIM-38 -- Source: Wos |
